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We measured glutathione (GSH) metabolism m normal NIH/3T3 fibroblasts. and m cells transformed by the oncogenes sis, r&B. SK. ras, dbl. 
and wJ: crhB. WC, T(IS and ruf. but not SLY and tlhl transformants. showed increased level uf total and reduced GSH as compared with normal NIH/3T3 
fibroblasts: oxAzed GSH was elevated only in JW and rub-transformed cells. Increased total GSH content was associated with decreased activity 
of the synthetic enzyme y-glutamylcysteine synthetase. and oxidized GSH level with Increased actl~ity of GSH reductase. These data suggest that 
GSH synthesis was selectively enhanced in cells transformed by specific oncogenes. %ith resultmg down-regulation of Its synthetic enzyme; 
alterations of GSH metabolism appeared to be pecuhar of transformation by specific oncogenes. and not trivial epiphenomena of neoplastlc 
transformation. Oncogenic transformants that presented elevated level of GSH were also those reported to be resistant to antmeoplastic drugs and 
lomzmg radiations. thus confirming a possible lmk between altered GSH metabolism and reststance to antmeoplastic treatment. 
Glutathione; Oncogene; Iomzmg radiation; Radiation therapy: Neoplasm 
1. INTRODUCTION 
Glutathione (GSH), which predominantly exists in 
the reduced form, is involved in regulation of several 
cell functions, including aminoacid transport [l], en- 
zyme activities, thiol-disulphide balance [2], synthesis 
of DNA precursors [3], and cell proliferation 141. GSH- 
related enzymes. i.e. GSH peroxidase (GPX) and GSH- 
S-transferase (GST). are involved in free radical scav- 
enging. peroxide reduction, and detoxification through 
formation of GSH-S conjugates [5.6]. High levels of 
GSH and related enzymes were observed in some cul- 
tures of transformed cells, and they were correlated with 
increased resistance to antineoplastic drugs and ionizing 
radiations [7-lo]. Depletion of intracellular GSH, 
achieved with inhibitors of GSH synthesis. restored sen- 
sitivity to antineoplastic agents, and conversely, phar- 
macologically-induced increase of GSH was associated 
with increased resistance [l l-141; thus, study of GSH 
Corvesponu’enre u&iress M.T Vmcenzim, Dept. of Biochemical Scl- 
ences, Vlale Morgagni 50. 50134 Flrenze. Italy. Fax, (39) (55) 412- 
2715. 
Abhrevmtlorls r-GSH. reduced glutathione, GSSG. oxidized glutathl- 
one: GSH, total glutatluone; GST, glutathlone-S-transferase (EC 
5.1.18). GPX. glutathione peroxidase (EC 1.11.1.9): GR. glutathlone 
reductase (EC 1.6.4.2); y-GCS. gamma-glutamyl cysteme sqnthetase 
(EC 6.3 2.2) 
metabolism might provide useful information for clini- 
cal diagnosis. and for prediction of tumor responsive- 
ness to antineoplastic treatment. 
We recently noted that transformation by oncogenes 
involved in mitogenic signal transduction was associ- 
ated with resistance to the killing effects of ionizing 
radiations. and we found a correlation between radi- 
oresistance and alterations of second messenger forma- 
tion [15]. In order to further investigate the molecular 
mechanisms responsible for oncogene-associated resis- 
tance, we studied GSH metabolism in NIH/3T3 fibro- 
blasts transformed by the oncogenes sis. e&B. SYC, rus, 
&I. and ruf which code for transforming protein inter- 
fering with signal transduction [16]: (i) sis codes for the 
BB-isoform of PDGF; (ii) v-erbB encodes a truncated 
form of the EGF receptor; (iii) the product of SI’C is a 
non-receptorial tyrosine kinase associated with the 
inner layer of the membrane; (iv) YUS codes for GTP- 
binding proteins (G proteins) involved in the transduc- 
tion of mitogenic signals: (v) dbl is involved in GDP/ 
GTP exchange at ras-like G-proteins; (vi) ruf codes for 
a cytoplasmic serine/threonine kinase bearing homol- 
ogy of sequence and function with protein kinase C. 
Detailed study of GSH metabolism in transformed lines 
included analysis of: reduced GSH (r-GSH); oxidized 
GSH (GSSG): total GSH (i.e. GSH = r-GSH + GSSG); 
GSH-redox index (GSSG/r-GSH); GST; GPX; the syn- 
thetic enzyme y-glutamylcysteine synthetase (y-GCS); 
and GSH reductase (GR). 
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2. MATERIALS AND METHODS GSH: mnol/mg protein/million cells 
CR, pnuvate dehydrogenase and lactate dehydrogenase used for 
GPX and y-GCS acttvtty assay were from Boehrmger and Soehne 
(Mannhetm. Germany) as well as coenzymes and substrates. All other 
chemicals were supphed by Merck (Darmstadt. Germany). Normal 
NIH/3T3 fibroblasts. and their counterpart transformed by the onco- 
genes rrhB, rus, +/I Arc. sis, and t/h/ were previously described [17] 
loo ft A: NIW3T3 
B: dbl * I 
Cells (3-10 x 10h) were centrifuged in a microcentrifuge (12,550 x g 
for 15 mm at 4°C). The precipttate was directly dissolved in 0.5 ml of 
5% aqueous HClO, and the cells were Iysed by somcation. Proteins 
were precipitated by centrifugation The supernatant was assayed for 
r-GSH and GSSG by HPLC as described by Reed and Fariss [I 81. In 
this method, the GSH auto-oxidation and the thtol-disulfide mter- 
change were prevented by rapid acidic extraction and addition of 
iodoacettc acid. The supernatant was neutralized by 2 M KCO, Then 
50 ~1 of 300 mM todoacettc acid. and 200 ,~l of 0.7 MKHCO, were 
added to 0.5 ml of extract. The resultmg alkalme solution was mcu- 
bated for 1 h at room temperature in complete darkness 0.1 ml of 5% 
(v/v) fluorodmitrobenzene dissolved m ethanol was added to the su- 
pernatant. which was then stored at 4°C overnight. The soluttons were 
analyzed by hqutd chromatography (Beckman Gold System eqmpped 
with an NEClPC 8201H computer, a Shimadzu C-R6A chromatopac 
Integrator, and a BIOSI~ NH? 90-5s BtoRad column). The 2.4dimtro- 
phenyl derivatives were detected at 360 nm. The r-GSH and GSSG 
were quantified relative to standards by Integration. 
60 
A B C D E F G 
Cell lines 
Fig. 1. GSH level m normal and transformed NIH/3T3 fibroblasts. 
Data are means + S.E.M (17 = 5. each expertment performed m duph- 
cate samples). Significantly different from NIH/3T3 cells. *P < 0.005. 
**p c 0.05. 
Cells (&IO x 10”) were centrifuged in a microcentrtfuge (12,550 x ,y 
for 15 min at 4°C). The precipitate was dtsaolved usmg 0.5 ml 150 mM 
Tris buffer containing 5 mM MgCI,. 2 mM DTT at pH 7.4. Cells were 
lysed by somcation at 4°C. The homogenate was centrifuged at 
15,000 x g for 25 mm. Except for GST. all enzyme activities were 
measured at 30°C by contmuous optical tests based on the extinction 
change of pyridme nucleotides at 340 nm usmg a Kontron (Uvtkon 
710) spectrophotometer. GPX was assayed usmg the procedure of 
Paglia and Valentine [19]. which uses H,02 as substrate The measured 
acttvity was corrected for the occurrence of any spontaneous reaction 
m the absence of the enzymes. The activity of CR &as determined 
usmg the method of Goldberg et al. [20] The activity of y-GCS was 
assayed by Seeling’s method [21]. GST was assayed with method of 
Habig et al. [22]. using I-chloro-2.4dimtrobenzene as substrate. The 
formation of .S-2,4-dmttrophenylglutathione was observed at 340 nm. 
All enzymatic acttvtties were expressed m terms of ~mollmmlmg of 
total protein. The protem concentration was determmated by 
Bradford’s method [23]. Bovme serum albumm (Sigma Chemical Co ) 
was used as the control standard 
was increased in erbB. I’LIS, rqf and SIY transformants, 
while GSSG was significantly elevated only in KIS-. and 
,r.rc.-transformed cells (Table I); GSH redox index, how- 
ever, did not change in any of the cell line tested. In 
order to evaluate these changes of the GSH system. we 
simultaneously determined the specific activities of en- 
zymes involved in GSH metabolism. Fig. 2A shows that 
cells transformed by the oncogenes I’LIS. SW, erhB and rcj 
had lower level of total GST activity (from 38% to 55% 
decrease) as compared with normal NIH/3T3. Analysis 
of y-GCS (i.e. the rate-limiting enzyme of GSH synthe- 
sis which is inhibited by negative feed-back) [24] re- 
vealed a similar pattern of decrease (Fig. 2B), that was 
significant for those transformants showing altered 
GSH metabolism. Unlike the latter two enzymes. GR 
(i.e. the enzyme responsible for GSSG reduction) spe- 
cific activity significantly increased by about 50% in I’US, 
The sigmficance of the disparities betueen the means observed m 
normal and transformed cells was evaluated usmg Student’s t-test. A 
difference of P < 0.05 was considered stgnificant. 
Table I 
Level of GSH system components m normal and transformed NlHl 
3T3 cell\ 
3. RESULTS Cell line r-GSH GSSG GSSG/r-GSH 
Fig. 1 demonstrates that NIH/3T3 fibroblasts trans- 
formed by the oncogenes erbB, YCIS, and SK exhibited a 
net increase of GSH as compared with normal cells: 
percent increase over GSH values obtained in normal 
cultures was of 9 l%, 120%, and 130%, respectively. r~lf- 
transformed fibroblasts showed a smaller, although sig- 
nificant, increase (61%) of GSH, whereas cell lines 
transformed by sis and &I did not show appreciable 
variations of GSH as compared with normal cells. De- 
tailed analysis of GSH metabolites revealed that r-GSH 
NIH/3T3 30 t 2 2.0 f 0.5 0.066 + 0 007 
tihl ‘8 + 3 2 1 2 0.1 0 071 ? 0.007 
JIJ 31 t 2.5 2.0 t 0.2 0.063 i 0.005 
ruf 50 & 5 2.5 + 0.1 0.050 + 0.002 
WhB 56 + 6* 3.5 2 0.3 0.04-l + 0.009 
rus 70 ? 3* 4.2 + 0.3** 0.057 _+ 0 004 
.m 70 f 6* 5.1 + 0.3* 0.071 ? 0 006 
r-GSH and GSSG are expressed as nmol/mg proteinimtllion cells. 
Data are means ? S E.M (II = 5; each experiment performed in dupli- 
cate samples). Stgniticantly different from NIH/3T?: *P < 0 005; 
**p < 0.05. 
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and src transformants (Fig. 2C), that exhibited the high- 
est GSSG levels. We also measured the activities of 
selenium-dependent and independent GPX which are 
involved in the reduction of hydrogen peroxide, lipoper- 
oxides, and hydroperoxides; however, the extremely low 
specific activities found in NIH/3T3 fibroblasts were 
well below the threshold of sensitivity of the described 
spectrophotometric method that we used [19], and no 
consistently reproducible results were obtained. Cells 
transformed by the oncogenes sis and dbl did not show 
alterations of GSH metabolism components (Table I, 
Figs. 1 and 2). 
Analysis of the relationship between the components 
of the GSH system and GSH-related enzymes in normal 
and transformed cells, revealed a negative correlation 
between GSH level and y-GCS specific activity (Fig. 
3A) as well as a positive correlation between GSSG 
levels and GR specific activity (Fig. 3B); coefficients of 
correlation as determined by linear regression analysis 
were 0.911 and 0.913, respectively. A negative correla- 
tion between GSH level and GST specific activity was 
also noted, although the correlation coefficient was 
lower (0.776). 
4. DISCUSSION 
Our study is the first attempt to link alterations of 
GSH metabolism with single oncogene transformation 
in in vitro immortalized cell lines. and our results indi- 
cate specific correlation between oncogene-induced 
transformation and altered GSH metabolism. Varia- 
tions of all components of GSH system and GSH-re- 
lated enzyme activities were observed in erbB, src. ras, 
and raf, but not in dbl and sis transformants, thus indi- 
cating that these alterations were not trivial epiphenom- 
ena of neoplastic transformation, but rather specific 
oncogene-related features. The present results confirm 
those previously reported concerning elevated GSH in 
rus transformants [8.25,26], and extend the field of re- 
search to other oncogenes and to detailed analysis of 
GSH metabolism. Interestingly. the oncogenic transfor- 
mants that presented elevated level of GSH were also 
those reported to be resistant to antineoplastic drugs 
and ionizing radiations [15]. thus confirming a possible 
link between altered GSH metabolism and resistance to 
antineoplastic treatment. Elevated GSH content might 
favour DNA repair following drug-, and radiation-in- 
duced injuries, as evidenced by inhibition of DNA re- 
pair following treatment with a specific inhibitor of y- 
GCS activity (buthionine sulphoximine) [ 12,131. Con- 
cerning the origin of elevated GSH content in specific 
transformants, we hypothesized that oncogene-induced 
transformation was associated with increased GSH syn- 
thesis as evidenced by down-regulation of its synthetic 
enzyme, y-GCS (Figs. 2B and 3A); consistently, recent 
data show acquired drug and radiation resistance by 
tumor cells following increased GSH synthesis [9]. 
A: GST, specific activity 
0,OS A: NIW3T3 
B: dbl 
ABCDEFG 
B: gamma-GCS, specific activity 
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Fig. 2. Specific actwlty of GSH-related enzymes in normal and trans- 
formed NlH/3T3 fibroblasts. Specific activity of enzymes are ex- 
pressed as micromoles per mm. per mg of total protem Data are 
means f S.E.M. (n = 5: each experiment performed m duplicate sam- 
ples). Significantly different from NIH/3T3 cells: *P < 0.005. 
**PC 0.001. 
221 









I ’ I * I ’ I * 
0.08 0,lO 0,12 0,14 0,16 0,18 
gamma-GCS 
GSSG B 
6'~ = - 2,8308 + 90,654x 





1-'q II I n I ' I ' 
0,04 0,05 0,06 0,07 0,08 0.09 
GR 
Fig. 3. Correlation between GSH and y-GCS 5pec1fic activity (A): 
correlation between GSSG and GR specific activity(B) in normal and 
transformed NIH/3T3 fibroblasts. GSH and GSSG are expressed as 
nmol/mg protein/million cells. Enzyme specific activities are expressed 
as pm01 min mg of total protein. 
Alteration of GSH content in neoplastic cells or in 
tumors was associated with reduction and detoxifica- 
tion processes which are in turn responsible for resis- 
tance to antineoplastic drugs and ionizing radiations 
[7710]; in particular, increased GSH content was inter- 
preted as an increased substrate demand for either GST 
or GPX, whose activities are involved in resistance to 
a wide range of chemotherapeutic drugs [7.13,27]. How- 
ever. a confusing picture emerged from past studies as 
alteration of GSH level in drug-resistant tumor cell lines 
was associated with no variation, increase or decrease 
of GST activity [7-9,28,29]; other studies reported both 
increase and decrease [13] of total GST activity in tumor 
samples compared with normal tissue. Our results show 
a net decrease of total GST activity in those cell lines 
with high level of GSH (Fig. 2A). together with non- 
detectable GPX activity (not shown). The interpretation 
of specific GST decrease is complex: counter-regulation 
of GST activity by mixed disulphides formation which 
is dependent on r-GSH and GSSG level [30], might offer 
an explanation. Moreover, reduced GST activity might 
further increase GSH level owing to reduced loss of 
GSH-S-conjugates. It appears that detoxification and 
reduction processes, and resistance to antineoplastic 
treatment are uncoupled; therefore, GSH metabolism 
might be involved in resistance through other, un- 
known, mechanism(s). 
The positive correlation between GSSG content. and 
specific GR activity (Figs. 2C and 3B) indicated efficient 
reduction of GSSG to r-GSH in oncogenic transfor- 
mants; thus GSH-redox index was unaltered in erbB, 
YCIS, src, and raf transformants that exhibited elevated 
r-GSH and GSSG levels. Increase GR activity could 
then be interpreted as substrate-induced. Alteration of 
GR activity and GSSG level were also associated with 
resistance to antineoplastic agents [7], although no data 
were previously reported in oncogene-transformed 
lines. 
In conclusion, our results demonstrate that onco- 
genes, whose products selectively interfere with specific 
passages of mitogenic signalling. cause profound altera- 
tions of GSH metabolism, thus proposing a link be- 
tween oncogenic transformation, mitogenic signalling, 
GSH metabolism, and resistance to antineoplastic treat- 
ment. 
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